Edesa Biotech, Inc. (EDSA)

Edesa Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2012	FY 2011
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Aug 31, 2012	Aug 31, 2011
Net Income	-7.21	-7.19	-6.17	-5.2	-3.6
Depreciation & Amortization	0.08	0.12	0.19	0.11	0.09
Stock-Based Compensation	1.02	0.73	0.54	1.92	1.74
Other Adjustments	-	-	-0.01	-1.22	-1.23
Change in Receivables	0.07	-0.38	0.36	0.03	0.53
Changes in Accounts Payable	1.76	-0.72	0.02	0.28	-0.14
Changes in Unearned Revenue	-	-	-	0.13	-
Changes in Other Operating Activities	-0.04	0.11	0.2	0	-0.01
Operating Cash Flow	-6.26	-7.32	-4.89	-3.95	-2.62
Capital Expenditures	-0.5	-	-	-0.08	-0.31
Other Investing Activities	0.02	-	-	-	-
Investing Cash Flow	-0.48	-	-	-0.08	-0.31
Long-Term Debt Repaid	-	-	-0.03	-	-
Net Long-Term Debt Issued (Repaid)	-	-	-0.03	-	-
Issuance of Common Stock	2.01	16.06	0.73	0.88	5.51
Repurchase of Common Stock	-	-	-	-	-0.13
Net Common Stock Issued (Repurchased)	2.01	16.06	0.73	0.88	5.39
Issuance of Preferred Stock	-	1.54	-	-	-
Net Preferred Stock Issued (Repurchased)	-	1.54	-	-	-
Other Financing Activities	-0.11	-0.57	-0.11	-	-0.04
Financing Cash Flow	1.9	17.03	0.59	0.88	5.07
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.13	0.05	-0.03	0	0
Net Cash Flow	-4.7	9.75	-4.32	-3.15	2.14
Free Cash Flow	-6.76	-7.32	-4.89	-4.03	-2.93
FCF Margin	-	-	-	-1407.48%	-419.91%
Free Cash Flow Per Share	-0.88	-1.29	-1.53	-270.40	-225.98
Levered Free Cash Flow	-7.99	-7.67	-5.8	-4.76	-3.97
Unlevered Free Cash Flow	-8.48	-8.4	-6.61	-5.65	-4.2

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q